2012
DOI: 10.3348/kjr.2012.13.4.505
|View full text |Cite
|
Sign up to set email alerts
|

Acute Severe Thrombocytopenia Following Non-Ionic Low-Osmolarity Intravenous Contrast Medium Injection

Abstract: Intravenous contrast medium (ICM) rarely induces anaphylactic reactions, including urticaria, hypotension and respiratory failure. Even the most modern ICM may cause such adverse events. Thrombocytopenia has been reported as an extreme rare consequence of ICM. Here we report on a case of a 72-year-old male patient with a self-limiting severe acute thrombocytopenia following administration of intravenous non-ionic low-osmolarity contrast medium. No such low platelet count has ever been reported. We also present… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
15
0

Year Published

2012
2012
2021
2021

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 17 publications
(15 citation statements)
references
References 9 publications
0
15
0
Order By: Relevance
“…The use of ICM is generally regarded to be safe. However, acute adverse reactions to current non-ionic ICM occur in 0.7–3.1% of patients and, although most reactions are confined to mild urticaria, they can be life-threatening (23). To manage adverse reactions to ICM, several clinical guidelines have been published based on recent studies and consensus statements by relevant expert committees such as the American College of Radiology (ACR), European Society of Urogenital Radiology (ESUR) (45), and Korean Network of Allergists & Radiologists for Research on Radiocontrast media-associated Adverse reactions (6).…”
Section: Introductionmentioning
confidence: 99%
“…The use of ICM is generally regarded to be safe. However, acute adverse reactions to current non-ionic ICM occur in 0.7–3.1% of patients and, although most reactions are confined to mild urticaria, they can be life-threatening (23). To manage adverse reactions to ICM, several clinical guidelines have been published based on recent studies and consensus statements by relevant expert committees such as the American College of Radiology (ACR), European Society of Urogenital Radiology (ESUR) (45), and Korean Network of Allergists & Radiologists for Research on Radiocontrast media-associated Adverse reactions (6).…”
Section: Introductionmentioning
confidence: 99%
“…Three cases of non-ionic contrast-induced acute severe thrombocytopenia have been reported so far: Two cases demonstrated acute thrombocytopenia following symptoms of immediate allergic reaction after contrast infusion ( Table 2 ). 4 5 The other case did not describe whether any signs or symptoms of allergic reaction were observed after contrast infusion or not. 7…”
Section: Discussionmentioning
confidence: 97%
“… 1 2 3 Non-ionic contrast-induced acute thrombocytopenia is far more rare and has been usually accompanied by signs or symptoms of immediate allergic reaction, including respiratory distress, chest discomfort, facial flushing, or skin rash. 4 5 …”
Section: Introductionmentioning
confidence: 99%
“…Acute severe thrombocytopenia is an extremely rare and severe adverse complication induced by contrast media. To the best of our knowledge, 16 cases of this serious adverse reaction have been reported with different types of contrast media since the early 1980s (Table 3) [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17]. In most patients, any symptoms, including bleeding, fever, chills, dyspnea, wheezing, abdominal pain, and blood pressure variability, were observed within 24 h after contrast administration and the platelet count was decreased to below 10,000/ μl.…”
Section: Discussionmentioning
confidence: 99%
“…The lowest reported value of the platelet count was 0/ μl [16]. With regard to treatment, high-dose intravenous corticosteroids, which are widely used in management of anaphylaxis, were used in nine patients [2,4,6,7,10,12,13,16,17]. Eight patients received platelet transfusions [3, 5-8, 10, 12, 17].…”
Section: Discussionmentioning
confidence: 99%